Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein
Translational study published in Thrombosis Research (2021)
Abstract
A pure recombinant staphylokinase-hirudin fusion protein (SFH) was obtained by recombinant genetic engineering and purification techniques. The thrombolytic and anticoagulant activities of SFH were investigated using in vitro coagulation models and chromogenic assays. The results showed that intact SFH had targeted thrombolytic activity, and gained anticoagulant activity when cleaved by FXa. In addition, we investigated the pharmacodynamics of SFH in vivo using a variety of animal models, including a rat inferior vena cava thrombosis model, a rat coronary thrombosis model, a rabbit carotid artery thrombosis model and a canine coronary thrombosis model. We found that SFH had an obvious thrombolytic effect and could prevent and reduce re-embolization after thrombolysis and reduce the serious bleeding side effects caused by the combination of thrombolytic and anticoagulant drugs. The results suggest that SFH can be used for thrombolytic therapy in thromboembolic diseases.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Recombinant staphylokinase-hirudin fusion protein (SFH) showed targeted thrombolytic and FXa-cleavage-activated anticoagulant activity across rat IVC, rat/canine coronary, and rabbit carotid artery thrombosis models with reduced bleeding compared to standard combinations.
Por qué esto importa para la hirudoterapia
Este estudio describe una proteína de fusión recombinante estafiloquinasa-hirudina (SFH) diseñada para combinar la actividad trombolítica dirigida (mediante estafiloquinasa) con la actividad anticoagulante liberada tras la escisión por el Factor Xa. La SFH demostró efectos trombolíticos y prevención de la reembolización con efectos secundarios hemorrágicos reducidos en múltiples modelos animales, incluyendo trombosis de la vena cava inferior y coronaria en rata, trombosis de la arteria carótida en conejo y trombosis coronaria en canino. Para ASH, esto es relevante porque aprovecha la hirudina en un terapéutico diseñado de doble función. ADVERTENCIA: todos los hallazgos provienen de modelos animales preclínicos y ensayos in vitro; no se presentan datos clínicos en humanos, y el resumen no reporta tamaños muestrales, análisis estadísticos ni brazos comparadores directos.
Citación
Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein.
Ren K et al. · Thrombosis Research, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026